A citation-based method for searching scientific literature

Shikha Saini, Ajay V Maker, Kenneth D Burman, Bellur S Prabhakar. Biochim Biophys Acta Rev Cancer 2019
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Future Oncol 2019
56
33

Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells.
Wenbo Zhu, Songmin He, Yan Li, Pengxin Qiu, Minfeng Shu, Yanqiu Ou, Yuehan Zhou, Tiandong Leng, Jun Xie, Xiaoke Zheng,[...]. Vascul Pharmacol 2010
28
33

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada. Thyroid 2017
39
33


Rescuing the function of mutant p53.
A N Bullock, A R Fersht. Nat Rev Cancer 2001
426
33

Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
Thanyawat Sasanakietkul, Timothy D Murtha, Mahsa Javid, Reju Korah, Tobias Carling. Mol Cell Endocrinol 2018
28
33

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
313
33

Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation.
Ana Sastre-Perona, Pilar Santisteban. Mol Endocrinol 2014
26
33

Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.
Rosa Linda Messina, Mariangela Sanfilippo, Veronica Vella, Giuseppe Pandini, Paolo Vigneri, Maria Luisa Nicolosi, Fiorenza Gianì, Riccardo Vigneri, Francesco Frasca. Int J Cancer 2012
36
33

Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.
Naoyoshi Onoda, Masanori Nakamura, Naoki Aomatsu, Satoru Noda, Shinichiro Kashiwagi, Kento Kurata, Shinya Uchino, Kosei Hirakawa. Mol Clin Oncol 2015
6
33

Buparlisib in breast cancer.
Bhawna Sirohi, Sameer Rastogi, Shaheenah Dawood. Future Oncol 2015
10
33

Management of anaplastic thyroid cancer.
Xavier M Keutgen, Samira M Sadowski, Electron Kebebew. Gland Surg 2015
57
33

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Cristian Massacesi, Emmanuelle Di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath,[...]. Onco Targets Ther 2016
158
33

The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
Motoyasu Saji, Matthew D Ringel. Mol Cell Endocrinol 2010
121
33

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Rong Bu, Abdul K Siraj, Sasidharan Padmaja Divya, Yan Kong, Sandeep Kumar Parvathareddy, Maha Al-Rasheed, Khadija A S Al-Obaisi, Ingrid G Victoria, Saif S Al-Sobhi, Mohammed Al-Dawish,[...]. Int J Cancer 2018
33
33

Targeting mutant p53 for cancer therapy.
Moshe Oren, Perry Tal, Varda Rotter. Aging (Albany NY) 2016
16
33

Use of vemurafenib in anaplastic thyroid carcinoma: a case report.
Kristen A Marten, Vinay K Gudena. Cancer Biol Ther 2015
22
33


BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
M E Cabanillas, A Patel, B P Danysh, R Dadu, S Kopetz, G Falchook. Horm Cancer 2015
36
33

Anaplastic thyroid cancer.
James Paul O'Neill, Ashok R Shaha. Oral Oncol 2013
73
33

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
Della Makower, Alla Rozenblit, Howard Kaufman, Morris Edelman, Maureen E Lane, James Zwiebel, Hilda Haynes, Scott Wadler. Clin Cancer Res 2003
117
33

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
478
33

Drug discovery and mutant p53.
Magda M Maslon, Ted R Hupp. Trends Cell Biol 2010
46
33

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
370
33

Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Heqing Yi, Xuemei Ye, Bin Long, Ting Ye, Lijun Zhang, Fengqin Yan, Yang Yang, Linfa Li. Cancer Biother Radiopharm 2017
13
33

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.
Lise Willems, Jerome Tamburini, Nicolas Chapuis, Catherine Lacombe, Patrick Mayeux, Didier Bouscary. Curr Oncol Rep 2012
139
33

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).
George Mihai Nitulescu, Denisa Margina, Petras Juzenas, Qian Peng, Octavian Tudorel Olaru, Emmanouil Saloustros, Concettina Fenga, Demetrios Α Spandidos, Massimo Libra, Aristidis M Tsatsakis. Int J Oncol 2016
192
33

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Tatiana C Schneider, Djoeke de Wit, Thera P Links, Nielka P van Erp, Jakobus J M van der Hoeven, Hans Gelderblom, Inge C F M Roozen, Manon Bos, Wim E Corver, Tom van Wezel,[...]. J Clin Endocrinol Metab 2017
42
33

p53 Family and Cellular Stress Responses in Cancer.
Johanna Pflaum, Sophie Schlosser, Martina Müller. Front Oncol 2014
163
33

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
183
33

Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.
Jinluan Li, Jianji Pan, Xianggao Zhu, Ying Su, Lingling Bao, Sufang Qiu, Changyan Zou, Yong Cai, Junxin Wu, Ivan W K Tham. Chin J Cancer Res 2013
9
33

Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer.
Hiroyuki Namba, Vladimir Saenko, Shunichi Yamashita. Arq Bras Endocrinol Metabol 2007
22
33

Going viral: a review of replication-selective oncolytic adenoviruses.
Christopher Larson, Bryan Oronsky, Jan Scicinski, Gary R Fanger, Meaghan Stirn, Arnold Oronsky, Tony R Reid. Oncotarget 2015
65
33

Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.
Anna Guerra, Vincenzo Di Crescenzo, Alfredo Garzi, Mariapia Cinelli, Chiara Carlomagno, Massimo Tonacchera, Pio Zeppa, Mario Vitale. BMC Surg 2013
61
33

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.
Guang-Xia Chen, Shu Zhang, Xiao-Hua He, Shi-Yu Liu, Chao Ma, Xiao-Ping Zou. Onco Targets Ther 2014
47
33

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
Loredana Urso, Fiorella Calabrese, Adolfo Favaretto, PierFranco Conte, Giulia Pasello. Crit Rev Oncol Hematol 2016
30
33

Phase II trial of sorafenib in metastatic thyroid cancer.
Richard T Kloos, Matthew D Ringel, Michael V Knopp, Nathan C Hall, Mark King, Robert Stevens, Jiachao Liang, Paul E Wakely, Vasyl V Vasko, Motoyasu Saji,[...]. J Clin Oncol 2009
396
33


Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.
Marilena Celano, Catia Mio, Marialuisa Sponziello, Antonella Verrienti, Stefania Bulotta, Cosimo Durante, Giuseppe Damante, Diego Russo. Mol Cell Endocrinol 2018
10
33


Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
489
33

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
E Galanis, S H Okuno, A G Nascimento, B D Lewis, R A Lee, A M Oliveira, J A Sloan, P Atherton, J H Edmonson, C Erlichman,[...]. Gene Ther 2005
121
33

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
146
33


Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
Shu-Fu Lin, Yu-Yao Huang, Jen-Der Lin, Ting-Chao Chou, Chuen Hsueh, Richard J Wong. PLoS One 2012
36
33


MDM2, MDMX and p53 in oncogenesis and cancer therapy.
Mark Wade, Yao-Cheng Li, Geoffrey M Wahl. Nat Rev Cancer 2013
704
33

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kevin B Kim, Maria E Cabanillas, Alexander J Lazar, Michelle D Williams, Deborah L Sanders, Joseph L Ilagan, Keith Nolop, Richard J Lee, Steven I Sherman. Thyroid 2013
134
33

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Annette M Lim, Graham R Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J Hicks, Grant A McArthur, Christopher Angel, Benjamin Solomon, Danny Rischin. J Natl Compr Canc Netw 2016
23
33

Targeting the PI3K signaling pathway in cancer therapy.
Chandra Bartholomeusz, Ana Maria Gonzalez-Angulo. Expert Opin Ther Targets 2012
153
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.